MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) – MARCH-PFIC
Primary objective: * To evaluate the efficacy of maralixibat vs placebo on the severity of pruritus in the primary cohort Secondary objectives: * To evaluate the efficacy of maralixibat vs. placebo on the frequency of pruritus in the primary cohort * To evaluate the efficacy of maralixibat vs. placebo on total serum bile acid (sBa) levels in the primary cohort * To evaluate the safety, tolerability, and PK of maralixibat vs placebo